Is Topgolf Callaway (MODG) Split Uncertainty Overshadowing Management’s Updated 2025 Guidance?

• In the fourth quarter of 2025, O'Keefe Stevens Advisory boosted its stake in Topgolf Callaway Brands by 821,039 shares, investing about US$8.66 million and lifting its holding to roughly 1.17 million shares, while Tapasya Fund exited after management did not complete a planned Topgolf–Callaway split by mid-2025.
• These opposing institutional moves highlight how some investors are focusing on management’s raised 2025 guidance and improving traffic and cost trends, while others are reacting to unresolved corporate restructuring plans.
• Against this backdrop, we’ll explore how O’Keefe Stevens Advisory’s increased stake and management’s higher 2025 guidance reshape Topgolf Callaway Brands’ investment narrative.

These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Topgolf Callaway Brands Investment Narrative Recap

To own Topgolf Callaway Brands, you need to believe the combination of experiential venues and golf equipment can convert strong traffic and brand engagement into sustainable profitability, despite recent losses and discounting pressure. The latest moves by O’Keefe Stevens Advisory and Tapasya Fund do not materially change the near term catalyst of improving Topgolf traffic, but they do underline the ongoing execution risk around any potential separation of the Topgolf business.

The most relevant recent announcement here is management’s decision in November 2025 to raise full year 2025 revenue guidance to US$3.90 billion to US$3.94 billion, with higher Topgolf venue revenue expectations driven by better traffic and cost control. That guidance increase sits directly against the backdrop of some investors exiting on restructuring uncertainty, and puts more emphasis on whether Topgolf can grow profitably without leaning too hard on discounts.

Yet while traffic is improving, investors should be aware that sustained discounting and unresolved spin or sale discussions could still...

Read the full narrative on Topgolf Callaway Brands (it's free!)

Topgolf Callaway Brands' narrative projects $4.1 billion revenue and $209.7 million earnings by 2028. This requires a 0.5% yearly revenue decline and an earnings increase of about $1.7 billion from -$1.5 billion today.

Uncover how Topgolf Callaway Brands' forecasts yield a $12.50 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community range widely, from US$2 to about US$22.20 per share, showing just how far apart private investors can be. Against that spread, the tension between improving Topgolf traffic helped by value offers and the risk that heavy discounting pressures margins gives you a clear reason to compare several viewpoints before deciding how this business might fit into your portfolio.

Explore 4 other fair value estimates on Topgolf Callaway Brands - why the stock might be worth less than half the current price!

Build Your Own Topgolf Callaway Brands Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Topgolf Callaway Brands research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Topgolf Callaway Brands research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Topgolf Callaway Brands' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com